It’s Never Too Early or Too Late—End the Epidemic of Alzheimer’s by Preventing or Reversing Causation From Pre-birth to Death

Clement L. Trempe¹ and Thomas J. Lewis²*

¹Independent Clinician, Nahant, MA, United States, ²RealHealth Clinics, Jefferson City, TN, United States

The path to sporadic Alzheimer’s is a tragic journey beginning prior to birth and ending in the most dreaded disease of society. Along the disease path are a myriad of clues that portend AD, many of which are complaints of seemingly unrelated conditions from chronic migraines, mood disorders, eye diseases, metabolic syndromes, periodontal diseases, hormonal and autoimmune diseases. Properly treating, not just managing, these diseases, prior to onset of dementia, may significantly reduce dementia incidences. Current high levels of health complaints reflect a state of generalized poor health and compromised immunity. During the mid-Victorian era, people were long-lived yet healthy, suffering from chronic diseases at one tenth the rate of peoples today. It’s our poor health, at any age that increases susceptibility to chronic diseases and Alzheimer’s. Infection is involved in many cases of Alzheimer’s and other neurodegenerative diseases but is also implicated in many chronic conditions. Scientists looking for causation recognize that Alzheimer’s is multifactorial and systemic—not “brain only.” To slow, stop and reverse the AD epidemic, identification and reversal of causal factors must occur across the entire life spectrum of humans. This approach simply gives consideration to enhancing immune status of our bodies and brain, and controlling inflammation and infection, throughout the entire age spectrum. Infection is a causal factor, but the root cause is multi-factorial and immune health related. Pasteur stated it best when acknowledging the work of Bernard in 19th Century France, “The seed is nothing, the soil is everything.”

Keywords: Alzheimer’s, infection, systemic, diabetes, congenital, immunity, prevention, inflammation

INTRODUCTION: IMMUNITY AND INFECTIOUS DISEASES

Historically, infectious diseases were the cause of morbidity and mortality. Infectious disease arguably continues to be the major driver of morbidity and mortality however this connection is largely ignored because of the occult nature of many of the causative agents and the cryptic cause and effect between organism and disease (Cochran et al., 2000). Dr. Paul Ewald explains how the concept of evolutionary fitness actually points to infection as being the major cause of disease in modern society (Cochran et al., 2000). Evolutionary fitness means the evolutionary success of an organism relative to competing organism. Genetic traits that may be unfavorable to an organism’s
survival or reproduction do not persist in the gene pool for very long. Natural selection weeds them out and any inherited disease or trait that has a serious impact on fitness must fade over time. Therefore, in considering common chronic conditions with severe health consequences, we may presume a non-genetic cause. According to Ewald (2002), “When diseases have been present in human populations for many generations and still have a substantial negative impact on people’s fitness, they are likely to have infectious causes.”

Immune system vitality may be the most important risk factor in any chronic disease including Alzheimer’s. The World Health Organization in “Risk Factors of Communicable Diseases” (World Health Organization, 2011) states, “Apart from symbiotic coexistence of human with micro-organisms, disease causing organisms breed in man-made unhygienic conditions of air water and soil. People with low immunity, weak, and living in unhygienic conditions are at greater risk for contracting the infections from surroundings.” This model of disease fits equally well with Alzheimer’s and other chronic diseases but has been limited because source of the infection is less obvious and diagnosis is not frequently enough made or considered.

Chronic inflammation is considered a cause of chronic disease, including Alzheimer’s (Rogers, 1995; Holmes et al., 2009; Kawai et al., 2018). As defined by Opie (1929) “Inflammation may be defined as the process by which cells and serum accumulate about an injurious agent and tend to remove or destroy it.” Chronic inflammation continues to be blamed for tissue damage but this complex cascade, stimulated by internal and external mediators, results in the release of danger signals that promote immune responses to antigens (Rock and Kono, 2008). Chronic, occult infection is a significant stimulator of chronic inflammation (Beatty et al., 1994). Host-pathogen interactions, defined as the importance of the host’s susceptibility for a microbe’s virulence, must be considered and this interrelationship is not straightforward. Casadevall and Pirofski (1999) proposed six different classes of host-pathogen interactions that helps explain how the relationship between infection, inflammation, immune health and disease, although apparent, may not always yield statistical certainty.

Rivas et al. (2017) explain that the current research paradigm is reductionist yet biological systems combine their limited elements, creating complex structures and solutions involving infectious diseases. The network theory of aging, and particular, inflamm-aging is defined as, “a global reduction in the capacity to cope with a variety of stressors and a concomitant progressive increase in proinflammatory status,” contributes to a more non-reductionist assessment of individualized health by measuring “many” rather than one or a few (Franceschi et al., 2000). The construct of inflamm-aging is a measure of immune system activity against chronic insult. Any chronic disease, then, is potentially a measure of the stress on the biological system and its ability, or lack thereof, to cope.

Chronic disease incidences, including Alzheimer’s, increases with older age and are linked to immunosenescence (Solana et al., 2012). Numerous studies show that the pathology of Alzheimer’s disease is present decades before a clinical diagnosis of dementia can be made (Mortimer et al., 2005). Predisposition to Alzheimer’s, therefore, is established prior to the acceleration of immunosenescence that starts around age 65 (Figure 1). The curve also represents the vulnerability to disease due to an immature immune system during the ages 0–5. It is during this time that the antecedents of Alzheimer’s and other chronic diseases, specifically occult infections, may opportunistically infiltrate such vulnerable hosts only to express as disease across the spectrum of time and lead to a significant upswing in Alzheimer’s. A comparison of a healthy and unhealthy person is also represented as are transient susceptibilities that may include acute health or sudden life changing events that adversely impact health.

There are numerous occult ectopic obligate intracellular pathogens linked to Alzheimer’s, including Chlamydia pneumoniae (CP; Balin et al., 1998), Borrelia burgdorferi (BB; Marquand and Muller, 1997), gram-negative aerobic bacteria of the oral cavity (Riviere et al., 2002), h-pylori (Malaguarnera et al., 2004), rickettsias (Morrison et al., 1991) and Toxoplasma gondii (Jung et al., 2012). Many infectious species are ubiquitous within both human and animal populations. CP expresses seroprevalence rates of over 50% among adults in the United States (Blasi et al., 2009). In some vulnerable individual, CP migrates to the brain and contributes to neurodegeneration (Gérard et al., 2006).

The connection between immune system health and infection extends back to the research of Bernard and Pasteur (Garko, 2012). Modern studies at MIT demonstrate a strong correlation between immunity and future Alzheimer’s (Dougherty, 2015). The CDC, in an article on neglected parasitic infections explain how, of the 60 million Americans infected with the Toxoplasma parasite, only a small proportion of the susceptible experience severe health consequences (Wong and Remington, 1994; Chaudhry et al., 2014; Jones et al., 2014). Higher prevalence of T. gondii in patients with AD compared to controls shows an association between organism and disease (Schulz et al.,
An estimated 18% of the United States are seropositive and worldwide, an estimated one third of the population are infected (Dalmi and Abdoli, 2012). Chronic infection is reported to reactivate toxoplasmosis (Montoya and Liesenfeld, 2004). For the individuals infected, any susceptibility factor illustrated in Figure 1 may contribute to toxoplasmosis proliferation and potential exacerbation of Alzheimer’s.

The CDC indicates that few infected with toxoplasmosis have symptoms. Yet, according to Kaiser Family Foundation, the highest percentage of medical spending occurs for ill-defined conditions (Peterson-Kaiser Health System Tracker, 2018). Toxoplasmosis and other occult organism likely contribute to these conditions and associated high cost of care. Stratton and Wheldon (2006) explains the life cycle of CP and its treatment when discovered associated with multiple sclerosis and heart diseases. Dr. Wheldon contributed the following list of disease presentations he associated with CP in his clinical practice over 20 years: cardiac conduction defects; effusive pericarditis with tamponade; chronic obstructive airways disease; multiple sclerosis; Alzheimer’s disease; chronic fatigue syndrome; encephalitis; retinal vasculitis; macular degeneration; progressive presbyopia; Crohn’s disease; new onset adult asthma; and schizophrenia (hebephrenia). A similar list associated with Toxoplasmosis may be established with more research.

Lyme disease, caused by vector spirochetes, is a well-recognized chronic disease precipitated from BB and co-infections. Miklossy hypothesized on a link between BB and Alzheimer’s in 1994 and proved a causal relationship (Miklossy, 1994, 2011). The CDC recently revised its estimate of 30,000 new cases per year in 2014 to 300,000+ in 2017 in the United States Kris Kristofferson was diagnosed with AD yet, after a discovery of Lyme disease, the public message was, “Kristofferson struggled with memory problems in recent years and was told he had Alzheimer’s disease, but it appears he was misdiagnosed and all along has actually been suffering from the tick-borne illness Lyme disease” (Marcus, 2016). The association and causation between infection and Alzheimer’s continues largely disregarded.

In “Overview of Lyme Disease: A Critique of an Ignored Pandemic,” Dr. Ken Stoller suggests that 20% of the human population is infected and may well explain diseases of unknown origin (Stoller, 2015). In a recently completed investigation of a cohort of 70 functioning but unhealthy manufacturing company workers in central Indiana, we evaluated 41 for stealth infection, including Lyme disease, based on reported lifestyle, symptoms, a broad array of inflammatory biomarkers, and serology testing. Of the 41, 40 were positive for at least one occult organism and most had two or more, 28 were found to have positive IGG titers for CP; 12 were positive for Toxoplasma Gondii; 18 were positive for at least one IGG band for Lyme; one was positive for Q Fever and one was positive for Rickettsia Typhii (Lewis et al., submitted). Presuming that the 30 untested individuals were negative for Lyme, these data support the estimated population infectious burden suggested by Stoller.

### PRE-BIRTH SUSCEPTIBILITY TO FUTURE AD

Congenital infections affect the unborn fetus or newborn infant. Conventionally, they are thought to be caused by viruses that may be picked up by the baby at any time during the pregnancy. Even if the mother is known to have a viral illness during her pregnancy, her immune system may prevent the virus from infecting the fetus or newborn infant. However, shortly after birth for mothers that do not breast feed or shortly after stopping breast feeding, the newborn’s immune system function drops precipitously and then slowly strengthens from ages 0–5, Figure 1.

Periodontal bacteria is a significant contributor to congenital infection. Offenbacher et al. (1996) were the first to report a relationship between maternal periodontal disease and delivery of a preterm infant. Global incidence of preterm birth is around 9.6% with regional disparities from 12% to 13% in USA, 5% to 9% in Europe, and 18% in Africa. According to “Born Too Soon,” the United States ranked 131st out of 184 in preterm births (Blencowe et al., 2013). Full term stillbirth is also caused by bacteria including Fusobacterium nucleatum (Han et al., 2010). The placenta is an immuno-suppressed organ compared to other organs like the liver and the spleen which makes it easy for the bacteria to colonize there. Intrauterine infection is considered a leading cause of early preterm birth and data from clinical and experimental studies suggest that infection accounts for upward of 40% of these high-risk preterm deliveries (Kravetz and Federman, 2005; Kemp et al., 2017).

Determining a statistical association between periodontal infection induced premature births and dementias is challenging because of the 70+ year gap between birth and disease. In “Birth in a High Infant Mortality State: Race and Risk of Dementia,” higher rates of dementia later in life was statistically connected to higher incidences of infant mortality in racial cohorts (Gilsanz et al., 2017). In a cohort of elderly individuals, blacks born in states with the highest levels of race specific infant mortality rates had 40% increased risk of dementia compared to national averages. Early life conditions may contribute to racial inequalities in dementia incidence according to the authors. Since infection accounts for a preponderance of preterm deliveries, one can surmise that the excess of dementia is tied back to either a failure to thrive at birth (poor immune status), chronic infection acquired during pregnancy, or a combination of these adverse circumstances, all of which add risk for future Alzheimer’s upon immunosenescence (Jeffcoat et al., 2002), Figure 1.

Non-periodontal infections are connected with both adverse pregnancy outcomes and dementias. Cytomegalovirus (CMV) infection in pregnancy causes adverse clinical outcomes and the rate of transmission in utero was reported at roughly 33% (Stagno et al., 1987). CMV is present in a very high proportion of brains from vascular dementia patients (Lin et al., 2002). It has also been implicated as a risk factor for Alzheimer’s (Barnes et al., 2014). Besides the inflammatory response elicited by infection, CMV may also drive immunosenescence and thus make an individual more susceptible to Alzheimer’s as a result.
of the infection or a co-infection acquired during any time in lifespan. According to Dow, “In immune competent individuals, infection with CMV is usually asymptomatic, even in neonates, but once established, its containment becomes a priority for the immune system, which is unable to completely eliminate it (Dow, 2015). However, even healthy immune competent people may display symptoms of CMV infection more often than previously appreciated, sometimes even with serious consequences and with age implicated as a risk factor. The consequences to the immune system for maintaining this constant CMV vigilance may be severe. Reports on the very young and the very old show that CMV infection results in similar alterations to CD8+ T cell subset surface phenotypes. This has given rise to the concept that what are apparent age-associated changes could rather be due to age-associated increases in prevalence of CMV infection.” This phenomenon may be driven by other pathogens as well with susceptibility and disease incident being explained by the proposed different classes of host-pathogen interactions (Casadevall and Pirofski, 1999).

EARLY LIFE SIGNS AND SUSCEPTIBILITY TO FUTURE AD

In the United States, the peak age at diagnosis for Type 1 diabetes (T1D) is 10–14 (Maahs et al., 2010). Genetics may play a role, but infection is strongly associated with the condition. T1D follows viral infections such as mumps, rubella, CMV, measles, influenza, encephalitis, polio, or Epstein-Barr virus. Viruses play an important role in the pathogenesis of T1D by inducing or accelerating the beta cell destruction process (Christen et al., 2012). Bacteria are also T1D associated agents. CP was found in 46.5% of young patients with T1D compared to 10.5% of non-diabetic controls (Rizzo et al., 2012). Additionally, CP antibody positivity was significantly more common in patients in poor metabolic control (HbA1c < 7%) and dysfunction of pancreatic beta cells (Rodriguez et al., 2015). Older patients with T1D have more than an 80% increased risk for dementia compared with those without diabetes and the risk is even higher when T2D subjects are excluded (Whitmer et al., 2015). Thus T1D, and more importantly the potential immune dysfunction and infection associated with the disease, are indicators of future AD.

YOUNG LIFE SIGNS AND SUSCEPTIBILITY TO FUTURE AD

More than 10% of all primary care office visits are depression- or mood-related (Stafford et al., 2000; Olsson et al., 2014). The research community knows that depression and Alzheimer’s disease are linked and its now clear that depression is a risk factor, not just a symptom, of AD (Dantzer et al., 2008; Wilson et al., 2010) A 17-year prospective study from the Framingham cohort demonstrates that older adults with depressive symptoms are at a 50% increased risk of developing Alzheimer’s disease (Saczynski et al., 2010). In another study, the authors showed an incident AD group compared to those without AD reported a barely perceptible increase in depressive symptoms during 6–7 years of observation before the diagnosis and no change during 2–3 years of observation after the diagnosis (Wilson et al., 2010). According to Caraci et al. (2010) the molecular mechanisms and cascades that underlie the pathogenesis of major depression, such as chronic inflammation and hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis, are also involved in the pathogenesis of AD (Caraci et al., 2010). Johnson et al. (2015) found that the signs of depression begin well before the symptoms of dementia begin manifesting. They believe that there are a core group of mood and depression symptoms, easily measureable in populations, that may enable medical professionals to differentiate between people at risk of developing dementia and normally aging individuals.

In “Latent Toxoplasmosis and Humans,” the authors review the impact of toxoplasmosis in the etiology of different mental disorders including schizophrenia and depressive disorders, obsessive-compulsive disorder, Alzheimer’s and Parkinson’s disease, epilepsy, headache and migraine, mental retardation, suicidal tendencies and intelligence (Dalimi and Abdoli, 2012). Toxoplasma gondii impairs memory in infected seniors without diagnosis of neurodegenerative disease. In a study of executive function and memory, subjects positive for Toxo showed memory performance reduction of about 35% compared to the toxo negative group and this group also reported a decreased quality of life compared to those not infected (Gajewski et al., 2014). In our own study cohort of 70 individuals, 40 were tested for IgG antibodies for toxoplasmosis and 12 were positive (Lewis et al., submitted).

The causal agent of Lyme is reported in mood disorder of young and middle-aged people (Fallon et al., 1993; Dersch et al., 2015). Determining causation from infection in mood disorders and suicidal tendencies suffers from crypticity. Garakani and Mitton (2015) state, “The patient’s panic attacks resolved after he was discharged and then, months later, treated with long-term antibiotics for suspected “chronic Lyme Disease” despite having negative Lyme titers” (Garakani and Mitton, 2015). A significant feature of post-treatment Lyme disease syndrome is depression (Rebman et al., 2017). Miklossy has provided adequate analysis to convince the most stubborn opponent of the relationship between BB and Alzheimer’s (Miklossy, 1994, 2011; Miklossy et al., 2004). Depression may be a clue as to the same infectious process and since depression generally precedes Alzheimer’s, treatments may be more effective.

YOUNG TO MIDDLE LIFE SIGNS AND SUSCEPTIBILITY TO FUTURE AD

The Rotterdam study revealed an increased risk of dementia and AD in patients with type 2 diabetes (T2D; Ott et al., 1999). Those with T2D are at 50% greater risk of developing a neurodegenerative condition compared to healthy contemporaries (Mayeda et al., 2015). Insulin resistance early
in life may enhance the risk of developing neurodegeneration (Luciano et al., 2015). Insulin resistance is due in part to infection, as first described in 1943 (Greene and Keohen, 1943). The article published in JAMA titled, “Insulin resistance due to infection in diabetes mellitus in man,” has not been widely cited. A modern version concludes that pathogen burden has the strongest association with insulin resistance among all the risk factors considered (Fernández-Real et al., 2006). For example, HSV-2 titer was negatively associated with insulin sensitivity even after factoring for inflammation. The relationship was strengthened further for subjects that were seropositive for CP and Enteroviruses. People with T2D are more prone to be on the “high susceptibility individual” curve of Figure 1.

MIDDLE LIFE SIGNS AND SUSCEPTIBILITY TO FUTURE AD

The eye is a canary for the brain because the retina is an embryonal outcropping of the brain (Dowling, 1987). Thus, anatomically and developmentally, the retina is an extension of the CNS; it consists of retinal ganglion cells, the axons of which form the optic nerve, whose fibers are, in effect, CNS axons. The eye has unique physical structures and a local array of surface molecules and cytokines, and is host to specialized immune responses similar to those in the brain and spinal cord. Several well-defined neurodegenerative conditions that affect the brain have manifestations in the eye, and ocular symptoms often precede CNS diagnoses by up to 20 years (London et al., 2013). Various eye-specific pathologies share characteristics of other CNS pathologies, including Alzheimer’s disease and glaucoma (McKinnon, 2003).

Immunoglobulin serology for CP is significantly higher in patients with glaucoma compared to controls (Yuki et al., 2010). Other infections noted in association with glaucoma include: Helicobacter pylori (Galloway et al., 2003), Bartonella henselae (Gray et al., 2004), HIV (Nash and Lindquist, 1992), CMV (Sekhsaria et al., 1992), Toxoplasmosis (Sheets et al., 2009), Tuberculosis (Egbagbe and Omoti, 2008), and Lyme disease (Zaidman, 1997). The eye is susceptible to inflammatory diseases through a delicate balance with survival coined “ocular immune privilege.” According to Streilein, “Not surprisingly, inflammation, if it occurs within the eye, is a profound threat to vision” (Hazlett and Stein-Streilein, 2012). Immune privilege and easy accessibility provides an explanation why neurodegeneration presents in the eye long before the brain in many cases and offers a low-cost early or pre-disease screening tool and link to treatable associations to future AD.

Macular degeneration is both a vascular and neurodegenerative disorder easily observed with simple yet elegant optometric instruments. Studies titled, “Age-related macular degeneration (AMD): Alzheimer’s disease in the eye?” (Kaarniranta et al., 2011) and “Parallel findings in age-related macular degeneration and Alzheimer’s disease,” (Ohno-Matsui, 2011) provide examples of what early neurodegenerative disease diagnosis could be. The less studied common denominator between macular disease and neurodegenerative diseases is infection. CP is a documented actor in age-related macular degeneration (Haas et al., 2009). Our own clinical evaluations, being compiled for publication, show seropositive CP and other occult infections in significant percentages of clinical AMD cases.

INFECTION, INFLAMMATION AND ALZHEIMER’S “HALLMARKS”

Balin et al. (1998) links CP to Alzheimer’s. Subsequently they have published dozens of articles on this topic including, “Proof of Concept Studies of Chlamydia Pneumoniae Infection as a Trigger for Late-onset Alzheimer Disease” (Balin, 2017). A Harvard-led team was the first to definitely show that the beta amyloid hallmark of AD is actually has antimicrobial properties (Soscia et al., 2010). Ravnskov and McCully explained that microvascular hypoxia is initiated by the sequestration of infectious remnants by LDL particles and this process is also noted in Alzheimer’s (Bailey et al., 2004; Ravnskov and McCully, 2009). Tau hyperphosphorylation is also noted in microvascular disease-associated neurodegenerative diseases (Castillo-Carranza et al., 2017). Hibernating animals also hyperphosphorylate tau and the common denominator between Alzheimer’s and hibernation may be hypoxia and, like with beta amyloid, the modified tau serves to protect the brain (Su et al., 2000). Corriveau et al. (2016) explain the significance of vascular contributions to cognitive impairment and dementia. Miklossy et al. (2006) noted increase in inflammation, beta-amyloid precursor protein, and hyperphosphorylated tau production induced by spirochetes or lipopolysaccharide. Balin (2017) delved into the link between the pathogens, inflammation, Abeta 1–42 production, regulation of gene transcripts, and protein expression. The conclusions regarding gene transcripts and protein expression are supported by studies of infectogenomics (Kellam and Weiss, 2006; Nibali et al., 2014). No other single explanation, other than infection, supports all the observed pathologies in Alzheimer’s.

CONCLUSION

Sub-optimal health and chronic inflammation predisposes individuals to opportunistic infections and a myriad of diseases throughout the continuum of life provide information about risk and susceptibility to future Alzheimer’s disease. Poor health status, periodontal diseases, congenital infections, depression, diabetes, eye diseases, to name a few, provide a roadmap of progression towards neurodegenerative disorders. Fundamental to the onset and propagation of all these diseases is immune system immaturity, dysfunction and senescence that facilitate proliferation of opportunistic infection. Clinically, medicine must change its paradigm of managing disease symptoms and adopt a proactive approach of testing for immune health status, by way of biomarkers of inflammation, to identify those at risk of future Alzheimer’s and other chronic diseases. Next, each at-risk subject must be provided guidance on how to improve their health status. In addition, those with compromised immune
status must also be tested for infection, and if found, treated until the burden is lowered or eradicated. This program must be conducted across the age spectrum for people showing signs and symptoms of any disease associated with Alzheimer’s in later life. This approach could conceivably delay Alzheimer’s onset by 5 years which could reduce number of incidences in half. When clinicians recognize association and causation between earlier chronic conditions and Alzheimer’s and focus on mitigation rather than management, a 50% or greater reduction in the disease becomes realistic.

REFERENCES

Bailey, T. L., Rivara, C. B., Rocher, A. B., and Hof, P. R. (2004). The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. *Neuro. Res.* 26, 573–578. doi: 10.1179/016164104225016272

Balin, B. J. (2017). Proof of concept studies of chlamydia pneumoniae infection as a trigger for late-onset Alzheimer disease. *Neurodegener. Dis.* 17:243. Available online at: https://www.karger.com/Journal/Home/223099

Balin, B. J., Gérard, H. C., Arking, E. J., Appelt, D. M., Branigan, P. J., Abrams, J. T., et al. (1998). Identification and localization of chlamydia pneumoniae in the Alzheimer’s brain. *Med. Microbiol. Immunol.* 187, 23–42. doi: 10.1007/s004300050071

Barnes, L. L., Capuano, A. W., Aiello, A. E., Turner, A. D., Robert Yolken, H., Torrey, E. F., et al. (2014). Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. *J. Infect. Dis.* 211, 230–237. doi: 10.1093/infdis/jiu347

Beatty, W. L., Byrne, G. I., and Morrison, R. P. (1994). Repeated and persistent infection with *Chlamydia* and the development of chronic inflammation and disease. *Trends Microbiol.* 2, 94–98. doi: 10.1016/0966-842x(94)90542-8

Blasi, F., Tarsia, P., and Alberti, S. (2009). *Chlamydohiphila pneumoniae*. *Clin. Microbiol. Infect.* 15, 29–35. doi: 10.1111/j.1469-0991.2008.02130.x

Blencowe, H., Couzens, S., Chou, D., Oestergaard, M., Say, L., Moller, A. B., et al. (2013). Born too soon: the global epidemiology of 15 million preterm births. *Reprod. Health* 10:52. doi: 10.1186/1472-4755-10-S1-52

Caraci, F., Copani, A., Nicolletti, F., and Drago, F. (2010). Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. *Eur. J. Pharmacol.* 626, 64–71. doi: 10.1016/j.ejphar.2009.10.022

Casenamevall, A., and Pirofski, L.-A. (1999). Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infect. Immun.* 67, 3703–3713.

Castillo-Carranza, D. L., Nilson, A. N., Van Skike, C. E., Jahrling, J. B., Patel, K., Garach, P., et al. (2017). Cerebral microvascular accumulation of tau oligomers in Alzheimer’s disease and related tauopathies. *Aging Dis.* 8, 257–266. doi: 10.14336/AD.2017.0112

Chaudhry, S. A., Gad, N., and Koren, G. (2014). Toxoplasmosis and pregnancy. *Can. Fam. Physician* 60, 334–336.

Christen, U., Bender, C., and von Herrath, M. G. (2012). Infection as a cause of type 1 diabetes? *Curr. Opin. Rheumatol.* 24, 417–423. doi: 10.1097/BOR.0b013e3283537179

Cochran, G. M., Ewald, P. W., and Cochran, K. D. (2000). Infectious causation of disease: an evolutionary perspective. *Perspect. Biol. Med.* 43, 406–448. doi: 10.1353/pbm.2000.0016

Corriveau, R. A., Bosetti, F., Emr, M., Gladman, J. T., Koenig, J. I., Moy, C. S., et al. (2016). The science of vascular contributions to cognitive impairment and practice good health and wellness. *Health and Wellness Monthly*. Available online at: http://www.letstalknutrition.com [Accessed on May 26, 2018].

Gérard, H. C., Dresse-Werringloer, U., Wildt, K. S., Deka, S., Ozust, C., Balin, B. J., et al. (2006). *Chlamydophila (Chlamydia) pneumoniae* in the Alzheimer’s brain. *FEMS Immunol. Med. Microbiol.* 48, 355–366. doi: 10.1111/j.1574-695x.2006.00154.x

Gilsanz, P., Mayeda, E. R., Glymour, M., Quesenberry, C. P., Mungas, D., DeCarli, C. S., et al. (2017). Birth in a high infant mortality state: race and risk of dementia. *Alzheimer Dement.* 13, P210–P211. doi: 10.1016/j.jalz.2017.07.082

Gray, A. V., Michels, K. S., Lauer, A. K., and Samples, J. R. (2004). Repeated and persistent infection and the risk for open-angle glaucoma. *Ophthalmol. N. Y. Acad.* 2015:457947. doi: 10.1155/2015/457947

Gorko, M. G. (2012). The terrain within: a naturalistic way to think about and practice good health and wellness. *Health and Wellness Monthly*. Available online at: http://www.letstalknutrition.com [Accessed on May 26, 2018].

Dougherty, E. (2015). Understanding the aging brain: new research from li-huei tsai’s lab suggests the immune system may play a role in Alzheimer’s disease. *Brain and Cognitive Sciences*. Available online at: https://bcn.mit.edu/news/events/news/understanding-aging-brain-new-research-li-huei-tsai’s-lab-suggests-immune-system [Accessed May on 27, 2018].

Dow, C. (2015). CMV driven immunosenescence and Alzheimer’s disease. *J. Neuro Infect.* 6:195. doi: 10.4172/2314-7326.1000195

Doming, J. E. (1987). The Retina: An Approachable Part of the Brain. Cambridge, MA: Harvard University Press.

Ebegue, E. O., and Omoti, A. E. (2008). Ocular disorders in adult patients with tuberculosis in a tertiary care hospital in Nigeria. *Middle East Afr. J. Ophthalmol.* 15, 73–76. doi: 10.4103/0974-9233.51996

Ewald, P. W. (2002). *Plague Time: The New Germ Theory of Disease*. Norwalk, MA: Anchor Press.

Fallon, B. A., Niedls, J. A., Parsons, B., Liebowitz, M. R., and Klein, D. F. (1993). Psychiatric manifestations of Lyme borreliosis. *J. Clin. Psychiatry* 54, 263–268.

Fernández-Real, J. M., López-Bermejo, A., Vendrell, J., Ferri, M. J., Recasens, M., and Ricart, W. (2006). Burden of infection and insulin resistance in healthy middle-aged men. *Diabetes Care* 29, 1058–1064. doi: 10.2337/diacare.2951058

Franceschi, C., Bonafé, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., et al. (2000). Inflammaging: an evolutionary perspective on immunosenescence. *Ann. N. Y. Acad. Sci.* 908, 244–254. doi: 10.1111/j.1077-5282.2000.tb06651.x

Gajewski, P. D., Falkenstein, M., Hensgler, J. G., and Golka, K. (2014). *Toxoplasma gondii* impairs memory in infected seniors. *Brain Behav. Immun.* 36, 193–199. doi: 10.1016/j.bbi.2013.11.019

Galloway, P. H., Warner, S. J., Morshed, M. G., and Mikelberg, F. S. (2003). *Helicobacter pylori* infection and the risk for open-angle glaucoma. *Ophthalmol. N. Y. Acad.* 110, 922–925. doi: 10.1016/s0161-6420/03/00093-9

Gurkan, A., and Mitton, A. G. (2015). New-onset panic, depression with suicidal thoughts and somatic symptoms in a patient with a history of Lyme disease. *Case Rep. Psychiatry* 2015:457947. doi: 10.1155/2015/457947

Gorko, M. G. (2012). The terrain within: a naturalistic way to think about and practice good health and wellness. *Health and Wellness Monthly*. Available online at: http://www.letstalknutrition.com [Accessed on May 26, 2018].

Beatty, W. L., Byrne, G. I., and Morrison, R. P. (1994). Repeated and persistent infection with *Chlamydia* and the development of chronic inflammation and disease. *Trends Microbiol.* 2, 94–98. doi: 10.1016/0966-842x(94)90542-8

Trempe and Lewis Stop Alzheimer’s Through Lifetime Prevention

AUTHOR CONTRIBUTIONS

TL and CT co-authored this work. The inspiration for this article is the clinical work of CT. TL is responsible for the research and assembly of the document.

FUNDING

This work was funded exclusively by the authors with no outside support.
Riviere, G. R., Riviere, K. H., and Smith, K. S. (2002). Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. *Oral Microbiol. Immunol.* 17, 113–118. doi: 10.1034/j.0902-0055.2001.00100.x

Rizzo, A., Paolillo, R., Iafusco, D., Prisco, F., and Romano Carratelli, C. (2012). *Chlamydia pneumoniae* infection in adolescents with type 1 diabetes mellitus. *J. Med. Microbiol.* 61, 1584–1590. doi: 10.1099/jmm.0.048512-0

Rock, K. L., and Kono, H. (2008). The inflammatory response to cell death. *Annu. Rev. Pathol.* 3, 99–126. doi: 10.1146/annurev.pathmechdis.3.121806.151456

Rodriguez, A. R., Plascencia-Villa, G., Witt, C. M., Yu, J.-J., José-Yacamán, M., Chambers, J. P., et al. (2015). *Chlamydia pneumoniae* promotes dysfunction of pancreatic β cells. *Cell. Immunol.* 295, 83–91. doi: 10.1016/j.cellimm.2015.03.010

Rogers, J. (1995). Inflammation as a pathogenic mechanism in Alzheimer’s disease. *Arzneimittelforschung* 45, 439–442.

Saczyński, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., and Au, R. (2010). Depressive symptoms and risk of dementia: the Framingham Heart study. *Neurology* 75, 35–41. doi: 10.1212/WNL.0b013e3181e62138

Schulz, P., Spannhorst, S., Iffland, B., and Toepper, M. (2007). Alzheimer’s disease and *Toxoplasma gondii* infection; seromolecular assess the possible link among patients. *Dement. Geriatr. Cogn. Disord.* 17, 181–187.

Sekhsaria, S., Rahbar, F., Fomufod, A., Mason, R., Kosoko, O., and Trouth, J. (1992). An unusual case of congenital cytomegalovirus infection with glaucoma and communicating hydrocephalus. *Clin. Pediatr.* 31, 503–507. doi: 10.1177/000992289203100811

Sheets, C., Grewal, D., and Greenfield, D. S. (2009). Ocular toxoplasmosis presenting with focal retinal nerve fiber atrophy simulating glaucoma. *J. Glaucoma* 18, 129–131. doi: 10.1097/IJO.0b013e318179f83f

Solana, R., Tarazona, R., Gayoso, L., Lesur, O., Dupuis, G., and Fulop, T. (2012). Innate immunoencephalence: effect of aging on cells and receptors of the innate immune system in humans. *Semin. Immunol.* 24, 331–341. doi: 10.1016/j.smim.2012.04.008

Soschia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., et al. (2010). The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide. *PLoS One* 5:e9505. doi: 10.1371/journal.pone.0009505

Stafford, R. S., Ausiello, J. C., Misra, B., and Saglam, D. (2000). National patterns of depression treatment in primary care. *Prim. Care Companion J. Clin. Psychiatry* 2, 211–216. doi: 10.4088/pcct.v02n0603

Stagno, S., Pass, R. F., Cloud, G., Britt, W. J., Henderson, R. E., Walton, P. D., et al. (1987). Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. *Obstet. Anesth. Digest.* 7:46. doi: 10.1097/00132582-198707000-00007

Stoller, K. P. (2015). Overview of Lyme disease: a critique of an ignored pandemic. *Int. J. Curr. Adv. Res.* 4, 409–414.

Stratton, C. W., and Wheldon, D. B. (2006). Multiple sclerosis: an infectious syndrome involving *Chlamydia pneumoniae*. *Trends Microbiol.* 14, 474–479. doi: 10.1016/j.tim.2006.09.002

Su, B., Wang, X., Drew, K. L., Perry, G., Smith, M. A., and Zhu, X. (2008). Physiological regulation of tau phosphorylation during hibernation. *J. Neurochem.* 105, 2098–2108. doi: 10.1111/j.1471-4159.2008.05294.x

Whitmer, R. A., Biessels, G. J., Quesenberry, C. P., Liu, J. Y., Karter, A. J., and Beeri, M. (2015). Type 1 diabetes and risk of dementia in late life: the Kaiser diabetes and cognitive aging study. *Alzheimers Dement.* 11, P179–P180. doi: 10.1016/j.jalz.2015.07.147

Wilson, R. S., Hoganson, G. M., Rajan, K. R., Barnes, L. L., Mendes de Leon, C. F., and Evans, D. A. (2010). Temporal course of depressive symptoms during the development of Alzheimer disease. *Neurology* 75, 21–26. doi: 10.1212/WNL.0b013e3181e620c5

Wong, S.-Y., and Remington, J. S. (1994). Toxoplasmosis in pregnancy. *Clin. Infect. Dis.* 18, 853–861. doi: 10.1093/clinids/18.6.853

World Health Organization. (2011). *The WHO STEP-Wise Approach Surveillance of Risk Factors For Non-Communicable Diseases*. Geneva: World Health Organization.

Yuki, K., Kimura, I., Shiba, D., Imamura, Y., and Tsubota, K. (2010). Elevated serum immunoglobulin G titers against *Chlamydia pneumoniae* in primary open-angle glaucoma patients without systemic disease. *J. Glaucoma* 19, 535–539. doi: 10.1097/IJO.0b013e3181ca7868

Zaidman, G. W. (1997). The ocular manifestations of Lyme disease. *Int. Ophthalmol. Clin.* 37, 13–28. doi: 10.1097/00004397-199703720-00003

**Conflict of Interest Statement**: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Trempe and Lewis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.